Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
NCT00657488
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
400
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
Thalidomide
Sponsor
Celgene